Edition:
United Kingdom

People: Flex Pharma Inc (FLKS.OQ)

FLKS.OQ on NASDAQ Stock Exchange Global Market

0.43USD
21 Sep 2018
Change (% chg)

$0.01 (+2.02%)
Prev Close
$0.42
Open
$0.41
Day's High
$0.45
Day's Low
$0.40
Volume
134,245
Avg. Vol
66,563
52-wk High
$8.95
52-wk Low
$0.40

Westphal, Christoph 

Dr. Christoph H. Westphal is re-designated as Chairman of the Board of the Company effective July 3, 2017. He is currently serves as Chairman of the Board, President, Chief Executive Officer.. Since February 2014. He has been served on the board of OvaScience, Inc. from 2011 to 2014. Dr. Westphal served as the President of SR One, the corporate venture capital arm of GlaxoSmithKline, from 2010 until 2011. Dr. Westphal has previously been involved in founding a number of biotechnology companies. Dr. Westphal co-founded Sirtris Pharmaceuticals, Inc., which was acquired by GlaxoSmithKline plc in 2008, and served as its Chief Executive Officer from 2004 to 2010. He also co-founded Alnara Pharmaceuticals, Inc., Concert Pharmaceuticals, Inc., Acceleron Pharma, Inc., serving as its Chief Executive Officer in 2003, Alnylam Pharmaceuticals, Inc., serving as its Chief Executive Officer in 2002, and Momenta Pharmaceuticals, Inc., serving as its Chief Executive Officer in 2001. Dr. Westphal serves on the Board of Fellows of Harvard Medical School and the Board of Overseers for the Boston Symphony Orchestra and is a member of the Research Advisory Council at the Massachusetts General Hospital. He earned his M.D. from Harvard Medical School, his Ph.D. in Genetics from Harvard University and his B.A. from Columbia University. The board of directors believes that Dr. Westphal's qualifications to sit on the Board include his experience as a senior executive, entrepreneur and venture capitalist and his service on the boards of directors of other life sciences companies.

Basic Compensation

Total Annual Compensation, USD 337,500
Restricted Stock Award, USD 375,804
Long-Term Incentive Plans, USD --
All Other, USD 172,603
Fiscal Year Total, USD 885,907

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --